From TGN1412 to TAB08: The return of CD28 superagonist therapy to clinical development for the treatment of rheumatoid arthritis

Clinical and Experimental Rheumatology

Volumn 34, Issue , 2016, Pages 45-48

  Tyrsin, Dmitry ^a,b   Chuvpilo, Sergey ^a,b   Matskevich, Alexey ^a,b   Nemenov, Daniil ^a   Römer, Paula S ^a,b   Tabares, Paula ^c   Hünig, Thomas ^c  

^a TheraMAB   (Germany)

^b University of Würzburg ^*  (Russian Federation)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Autoimmunity; CD28; CD28 superagonist; Regulatory T cells; Rheumatoid arthritis; TAB08; TGN1412

Indexed keywords

CD28 ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 2; T LYMPHOCYTE RECEPTOR; TGN 1412; ANTIRHEUMATIC AGENT; CYTOKINE; MONOCLONAL ANTIBODY; TGN-1412 MONOCLONAL ANTIBODY;

ARTICLE; AUTOIMMUNE DISEASE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOKINE RELEASE; CYTOKINE RELEASE SYNDROME; CYTOKINE STORM; DRUG DOSE INCREASE; DRUG SAFETY; FEVER; HUMAN; INFLAMMATORY DISEASE; LOW DRUG DOSE; LYMPHOCYTE PROLIFERATION; MEMORY T LYMPHOCYTE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PSORIASIS; REGULATORY T LYMPHOCYTE; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; ANIMAL; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; DISEASE MODEL; DRUG EFFECTS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MOLECULARLY TARGETED THERAPY; RISK ASSESSMENT; SIGNAL TRANSDUCTION;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD28; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CYTOKINES; DISEASE MODELS, ANIMAL; HUMANS; LYMPHOCYTE ACTIVATION; MOLECULAR TARGETED THERAPY; RISK ASSESSMENT; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, REGULATORY;

EID: 84984801011     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. + regulatory T cells in systemic autoimmune diseases. Autoimmun Rev 2011; 10: 744-55.
2. BURZYN D, KUSWANTO W, KOLODIN D et al.: A special population of regulatory T cells potentiates muscle repair. Cell 2013; 155: 1282-95.
3. CIPOLLETTA D: Adipose tissue-resident regulatory T cells: phenotypic specialization, functions and therapeutic potential. Immunology 2014; 142: 517-25.
4. + regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood 2006; 108: 1571-9.
5. KLATZMANN D, ABBAS AK: The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases. Nat Rev Immunol 2015; 15: 283-94.
6. + T cells expressing the FoxP3 transcription factor. Immunity 2009; 30: 899-911.
7. WEBSTER KE, WALTERS S, KOHLER RE et al.: In vivo expansion of T reg cells with IL-2-mAb complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression. J Exp Med 2009; 206: 751-60.
8. KONIG M, RHARBAOUI F, AIGNER S, DALKEN B, SCHUTTRUMPF J: Tregalizumab -a monoclonal antibody to target regulatory T cells. Front Immunol 2016; 7: 11.
9. HUNIG T: Manipulation of Regulatory T-Cell Number and Function with CD28-Specific Monoclonal Antibodies. Adv Immunol 2007; 95: 111-48.
10. SUNTHARALINGAM G, PERRY MR, WARD S et al.: Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006; 355: 1018-28.
11. + effector memory T-cells. Br J Pharmacol 2010; 161: 512-26.
12. RöMER P, BERR S, AVOTA E et al.: Preculture of PBMS at high cell density increases sensitivity of T-cell responses, revealing cytokine release by CD28 superagonist TGN1412. Blood 2011; 118: 6772-82.
13. TACKE M, HANKE G, HANKE T, HUNIG T: CD28-mediated induction of proliferation in resting T cells in vitro and in vivo without engagement of the T cell receptor: evidence for functionally distinct forms of CD28. Eur J Immunol 1997; 27: 239-47.
14. DENNEHY KM, ELIAS F, NA SY, FISCHER KD, HUNIG T, LUHDER F: Mitogenic CD28 Signals require the exchange factor Vav1 to enhance TCR signaling at the SLP-76-Vav-Itk signalosome. J Immunol 2007; 178: 1363-71.
15. LEVIN SE, ZHANG C, KADLECEK TA, SHOKAT KM, WEISS A: Inhibition of ZAP-70 kinase activity via an analog-sensitive allele blocks T cell receptor and CD28 superagonist signaling. J Biol Chem 2008; 283: 15419-30.
16. LIN C-H, HUNIG T: Efficient expansion of regulatory T-cells in vitro and in vivo with a CD28 superagonist. Eur J Immunol 2003; 33: 626-38.
17. BEYERSDORF N, GAUPP S, BALBACH K et al.: Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis. J Exp Med 2005; 202: 445-55.
18. (+) regulatory T cell activity: it takes (IL-)two to tango. Eur J Immunol 2005; 35: 1336-41.
19. + regulatory T cells are activated in vivo by recognition of self. Int Immunol 2007; 19: 557-66.
20. DENNEHY KM, ELIAS F, ZEDER-LUTZ G et al.: Cutting edge: monovalency of CD28 maintains the antigen dependence of T cell costimulatory responses. J Immunol 2006; 176: 5725-9.
21. LANGENHORST D, GOGISHVILI T, RIBECHINI E et al.: Sequential induction of effector function, tissue migration and cell death during polyclonal activation of mouse regulatory T-cells. PLoS One 2012; 7: e50080.
22. HANKE T: Lessons from TGN1412. Lancet 2006; 368: 1569-70; author reply 70.
23. STEBBINGS R, FINDLAY L, EDWARDS C et al.: "Cytokine storm" in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics. J Immunol 2007; 179: 3325-31.
24. ROMER PS, BERR S, AVOTA E et al.: Preculture of PBMCs at high cell density increases sensitivity of T-cell responses, revealing cytokine release by CD28 superagonist TGN1412. Blood 2011; 118: 6772-82.
25. WEGNER J, HACKENBERG S, SCHOLZ CJ et al.: High-density preculture of PBMCs restores defective sensitivity of circulating CD8 T cells to virus-and tumor-derived antigens. Blood 2015; 126: 185-94.
26. TABARES P, BERR S, ROMER PS et al.: Human regulatory T cells are selectively activated by low-dose application of the CD28 superagonist TGN1412/TAB08. Eur J Immunol 2014; 44: 1225-36.
27. SCHMIDT J, ELFLEIN K, STIENEKEMEIER M et al.: Treatment and prevention of experimental autoimmune neuritis with superagonistic CD28-specific monoclonal antibodies. J Neuroimmunol 2003; 140: 143-52.
28. TISCHNER D, WEISHAUPT A, van den BRANDT J et al.: Polyclonal expansion of regulatory T cells interferes with effector cell migration in a model of multiple sclerosis. Brain 2006; 129: 2635-47.
29. GOGISHVILI T, LANGENHORST D, LUHDER F et al.: Rapid regulatory T-cell response prevents cytokine storm in CD28 superagonist treated mice. PLoS ONE 2009; 4: e4643.
30. RODRIGUEZ-PALMERO M, FRANCH A, CASTELL M et al.: Effective Treatment of Adjuvant Arthritis with a Stimulatory CD28-specific Monoclonal Antibody. J Rheumatol 2006; 33: 110-8.
31. WIN SJ, KüHL AA, SPARWASSER T, HüNIG T, KAMRADT T: In vivo activation of Treg cells with a CD28 superagonist prevents and ameliorates chronic destructive arthritis in mice. Eur J Immunol 2016; 46: 1193-202.
32. ZAISS MM, FREY B, HESS A et al.: Regulatory T cells protect from local and systemic bone destruction in arthritis. J Immunol 2010; 184: 7238-46.
33. van den BRANDT J, FISCHER HJ, WALTER L, HUNIG T, KLOTING I, REICHARDT HM: Type 1 diabetes in BioBreeding rats is critically linked to an imbalance between Th17 and regulatory T cells and an altered TCR repertoire. J Immunol 2010; 185: 2285-94.
34. MIYASATO K, TAKABATAKE Y, KAIMORI J et al.: CD28 superagonist-induced regulatory T cell expansion ameliorates mesangioproliferative glomerulonephritis in rats. Clin Exp Nephrol 2011; 15: 50-7.
35. CHEN J, XIE L, TOYAMA S, et al.: The effects of Foxp3-expressing regulatory T cells expanded with CD28 superagonist antibody in DSS-induced mice colitis. Int Immunopharmacol 2011; 11: 610-7.
36. GUILLIAMS M, BOSSCHAERTS T, HERIN M et al.: Experimental expansion of the regulatory T cell population increases resistance to African trypanosomiasis. J Infect Dis 2008; 198: 781-91.
37. BEYERSDORF N, DING X, HUNIG T, KERKAU T: Superagonistic CD28 stimulation of allogeneic T cells protects from acute graftversus-host disease. Blood 2009; 114: 4575-82.
38. KITAZAWA Y, LI XK, LIU Z et al.: Prevention of graft-versus-host diseases by in vivo sup-CD28mAb-expanded antigen-specific nTreg cells. Cell Transplant 2010; 19: 765-74.
39. KITAZAWA Y, FUJINO M, SAKAI T et al.: Foxp3-expressing regulatory T cells expanded with CD28 superagonist antibody can prevent rat cardiac allograft rejection. J Heart Lung Transplant 2008; 27: 362-71.
40. AZUMA H, ISAKA Y, LI X et al.: Superagonistic CD28 antibody induces donor-specific tolerance in rat renal allografts. Am J Transplant 2008; 8: 2004-14.
41. URAKAMI H, OSTANIN DV, HUNIG T, GRISHAM MB: Combination of donor-specific blood transfusion with anti-CD28 antibody synergizes to prolong graft survival in rat liver transplantation. Transplant Proc 2006; 38: 3244-6.
42. SHI Q, NIU Y, CAO H et al.: CD28 superagonist antibody treatment attenuated obliterative bronchiolitis in rat allo-orthotopic tracheal transplantation by preferentially expanding Foxp3-expressing regulatory T cells. Transplant Proc 2012; 44: 1060-6.
43. NA SY, MRACSKO E, LIESZ A, HUNIG T, VELTKAMP R: Amplification of regulatory T cells using a CD28 superagonist reduces brain damage after ischemic stroke in mice. Stroke 2015; 46: 212-20.
44. + T cells improve healing after myocardial infarction by modulating monocyte/macrophage differentiation. Circ Res 2014; 115: 55-67.